NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd
Post# of 122
(Total Views: 155)
Posted On: 12/20/2022 2:35:07 PM
NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Closes $8M Underwritten Public Offering
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the closing of its underwritten public offering with gross proceeds to the company to be $8,000,000. The offering consists of 1,600,000 units and pre-funded units, with each unit consisting of one American Depositary Share (“ADS”) and two warrants, each to purchase one ADS. Each pre-funded unit consists of one pre-funded warrant to purchase one ADS and two warrants each to purchase one ADS. BiondVax expects to use the net proceeds, together with its existing cash and cash equivalents, for the advancement of its NanoAbs development program and general corporate purposes, which may include working capital, research and development activities, regulatory matters, capital investment or other related purposes. Aegis Capital Corp. acted as the sole book-running manager for the offering.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the closing of its underwritten public offering with gross proceeds to the company to be $8,000,000. The offering consists of 1,600,000 units and pre-funded units, with each unit consisting of one American Depositary Share (“ADS”) and two warrants, each to purchase one ADS. Each pre-funded unit consists of one pre-funded warrant to purchase one ADS and two warrants each to purchase one ADS. BiondVax expects to use the net proceeds, together with its existing cash and cash equivalents, for the advancement of its NanoAbs development program and general corporate purposes, which may include working capital, research and development activities, regulatory matters, capital investment or other related purposes. Aegis Capital Corp. acted as the sole book-running manager for the offering.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)BiondVax Pharmaceuticals Ltd. (BVXV) Stock Research Links
Scroll down for more posts ▼